Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097240 · ClinicalTrials.gov registry record
An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)
A clinical trial of Pregnancy and Psoriasis, sponsored by Genentech.
- Completed
- Registry status
- 18
- Enrollment target
- 1
- Study location
NCT00097240 is a study of Pregnancy and Psoriasis that has completed, run by Genentech. The registered enrollment target is 18 participants, below the 873-participant average among 191 other Pregnancy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00097240, a study of Pregnancy and Psoriasis, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The Raptiva Pregnancy Registry was a prospective observational study established to obtain data on pregnancy outcomes of women who were exposed to Raptiva.
Study Locations (1)
North Carolina
- FOLLOW Raptiva Pregnancy Registry - Morrisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097240
The ClinicalTrials.gov registry entry for NCT00097240 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 873-participant average among 191 other Pregnancy trials with a reported enrollment target (98% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 0 interventions.
NCT00097240 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00097240 about?
NCT00097240 is a clinical study titled "An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)". The Raptiva Pregnancy Registry was a prospective observational study established to obtain data on pregnancy outcomes of women who were exposed to Raptiva.
What is the current status of trial NCT00097240?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2005-01. Estimated completion is 2009-09.
What conditions does trial NCT00097240 study?
This clinical trial studies the following conditions: Pregnancy, Psoriasis.
Who is sponsoring clinical trial NCT00097240?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00097240 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
RECRUITING
-
Cocooned Moms Study
RECRUITING · NA
-
Retinal Vascular Changes During Pregnancy
RECRUITING
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.